Ureter Cancer, Urethra Cancer, Transitional Cell Carcinoma of Bladder and Malignant Tumor of Renal Pelvis Clinical Trial Using ALT-801, Gemcitabine and Cisplatin

- The folks at Altor Bioscience Corporation are studying the effects of Cisplatin; Gemcitabine; ALT-801 on Ureter Cancer, Urethra Cancer, Transitional Cell Carcinoma of Bladder and Malignant Tumor of Renal Pelvis in individuals ages 18 years and older. This clinical trial is slated to start June 2011 and is expected to end circa June 2014.

Overall Study Contact Info
StatusName Contact Phone
Recruiting

This study is officially titled, "A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer."

Locations

St. Luke's Hospital and Health Network

Easton, Pennsylvania - Recruiting

Carolinas Medical Center

Charlotte, North Carolina - Recruiting

University of Rochester Wilmont Cancer Center

Rochester, New York - Recruiting

Karmanos Cancer Center

Detroit, Michigan - Recruiting

University of Kansas Cancer Center

Fairway, Kansas - Recruiting

University of Iowa Hospitals and Clinics

Iowa City, Iowa - Recruiting

Robert Lurie Comprehensive Cancer Center of Northwestern University

Chicago, Illinois - Recruiting

Emory University

Atlanta, Georgia - Recruiting

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida - Recruiting

Martin Health System

Stuart, Florida - Recruiting

M.D. Anderson Cancer Center Orlando

Orlando, Florida - Recruiting

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.